Page 5 - Limmatech Biologics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Limmatech biologics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Limmatech Biologics Today - Breaking & Trending Today

Griffith University and LimmaTech Biologics sign landmark deal to develop gonorrhoea vaccine

Millions of lives are set to be changed for the better thanks to a landmark deal between Griffith University and Swiss-based company LimmaTech Biologics AG to develop a world-first gonorrhoea vaccine. ....

Michael Kowarik , Kate Seib , Eloise Keeffe , Mike Jennings , Limmatech Biologics , Griffith University , Griffith Institute For Glycomics , Institute For Glycomics , Glycomics Director Professor Mark , Commercial Manager , Investment Queensland , Scientific Officer Dr Michael Kowarik , First Peoples , Australian Microbial Strategy ,

LimmaTech Enters Exclusive License and Collaboration Agreement with Griffith University to Expand its Vaccine Technology Platform

LimmaTech Enters Exclusive License and Collaboration Agreement with Griffith University to Expand its Vaccine Technology Platform
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Paul Wolfrom , Michael Kowarik , Michael Jennings , Kate Seib , Gretchen Schweitzer , Limmatech Biologics , Griffith University , Trophic Communications , Institute For Glycomics At Griffith University , Griffith University In Queensland , Wall Street , Professors Michael Jennings , Chief Scientific Officer ,

LimmaTech in exclusive license agreement with Griffith University to expand its vaccine technology platform | Companies

LimmaTech Biologics announced a license and collaboration agreement with Griffith University in Queensland, Australia, to develop vaccines that prevent diseases with significant unmet medical need caused by emerging antibiotic resistant strains. ....

Limmatech Biologics , Griffith University In Queensland , Griffith University , Limmatech Biologics Announceda License And Collaboration Agreement With Griffith University In Queensland , O Develop Vaccines That Prevent Diseases With Significant Unmet Medical Need Caused By Emerging Antibiotic Resistant Strains ,

GlycoEra AG Raises CHF 45 Million (US$ 49 Million) Series A Financing to Develop Novel Biologics Based on Innovative Glycoengineering Platform

Financing round co-led by 5AM Ventures, Roche Venture Fund and Sofinnova Partners with participation from LimmaTech Biologics AG GlycoEra AG announced today the close of a CHF 45 million ($49 million) ....

United States , France General , South San Francisco , City Of , United Kingdom , San Francisco , Graziano Seghezzi , Graziano Seghezzi Sofinnova , Veronica Gambillara Fonck , Amir Faridmoayer , Ganesh Kaundinya , Kostenloser Wertpapierhandel , Glycoera Customglycan , Mira Chaurushiya , Laura Mittmann , Monique Schiersing Roche Venture Fund , Trophic Communications , Roche Venture Fund , Sofinnova Partners , Limmatech Biologics , Customglycan Platform , Monique Schiersing , Chief Scientific Officer , Managing Partner , Roche Venture , Jacob Verghese ,

Philippe Dro Joins Adjuvant Capital as Partner

Philippe Dro Joins Adjuvant Capital as Partner
Biopharma and Medical Device Entrepreneur Joins to Strengthen Global Health Investment Team and Establish a Formal Presence in Europe
News provided by
Share this article
NEW YORK, April 29, 2021 /PRNewswire/
Adjuvant Capital, a life science investment firm focused on global health, today announced that Phillipe Dro, Pharm. D., MBA, will join as a partner and be based in Zurich, Switzerland. As a seasoned biopharma and medical device entrepreneur and executive with more than 25 years of experience, Dr. Dro brings significant operational, scientific, technical and product development expertise to the Adjuvant Capital team. He is currently chairman of the Board of Amsterdam-based Scenic Biotech, as well as Swiss companies, Luciole Medical and LimmaTech Biologics. ....

New York , United States , San Francisco , Glenn Rockman , Limmatech Biologics , Antares Pharma , Merck Co , Phillipe Dro , Adjuvant Capital , Amsterdam Based Scenic Biotech , Luciole Medical , Supervisory Board , Swiss Based Glycovaxyn , G Protein Coupled Receptor , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , சான் பிரான்சிஸ்கோ , க்ளென் ராக்மேன் , அண்டர்ஸ் பார்மா , மெர்க் இணை , லூசியோல் மருத்துவ , மேற்பார்வை பலகை ,